Lung Cancer
daiich sankyo DS7300-188
|
Title in German |
Eine Phase-III-Studie zu I-DXd bei Patienten mit einem ersten Rückfall von kleinzelligem Lungenkrebs (SCLC) |
|
Title in English |
A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (l-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician’s Choice (TPC) in Subjects with Relapsed Small Cell Lung Cancer (SCLC) (IDeate-LungO2) |
|
Description |
This study compares the efficacy and safety of ifinatamab deruxtecan (I-DXd) with treatment of physician's choice (TPC) in participants with a first relapse of small cell lung cancer (SCLC). The study is divided into three periods: screening, treatment, and follow-up, including long-term survival follow-up. The screening period lasts a maximum of 28 days, with one re-screening possible if needed. The treatment period begins with randomization; the study drug is administered until disease progression or until other defined criteria are met. Radiological tumor assessments are performed regularly. The follow-up period begins after treatment discontinuation with the assessment of safety and survival. Participants remain in the study until their death, withdrawal from the study, or the end of the study. The study will end when all participants have completed treatment and follow-up, when alternative treatment options become available, or when the study is terminated by the sponsor. The study will last approximately 4.5 years. |
|
Phase/Biobank/etc. |
3 |
|
Head Clinical Trial |
|
|
Study-Nurse |
|
|
Back-up |
|
|
Status |
on hold: October 2025 |
|
BASEC-Nummer |
2024-01281 |
|
KOFAM |
SNCTP000006036 |
|
WHO-Register-Nummer |
NCT06203210 |
|
Insel-Nummer |
6021 |
EORTC 1901 (PRIMALung study)
|
Title in German |
PRophylaktische Hirnbestrahlung oder aktive MAgnetresonanztomografische Überwachung von Patienten mit kleinzelligem Lungenkarzinom (PRIMALung-Studie) |
|
Title in English |
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study) |
|
Description |
Patients with small cell lung cancer are usually treated with a combination of chemotherapy and radiation to the chest, and in some cases additional immunotherapy (drugs that stimulate the body's immune system). |
|
If the carcinoma spreads to the rest of the body (metastases), in many cases the brain is affected. Although brain irradiation is accepted as standard of care, current concerns about nervous system damage and the possibility of brain MRIs (magnetic resonance imaging) may make active monitoring a potentially better alternative to routine brain irradiation. In addition, there are open questions to be clarified about the role and timing of brain irradiation with increased use of immunotherapy. |
|
|
The aim of this study is to find out whether active surveillance via brain MRIs (magnetic resonance imaging) detects potential metastases in the brain earlier and leads to appropriate treatment without having a negative impact on survival compared to brain radiation when used in addition to brain metastases MRI monitoring is done. |
|
|
To find out whether the results of active monitoring via brain MRI are not caused purely by chance, we need to compare data from patients who were actively followed up via brain MRI with those from patients who received preventative brain irradiation. |
|
|
Therefore, the study participants are randomly assigned to one of two groups. One group receives daily preventive brain radiation for approximately 2 weeks and is then actively followed up via brain MRIs for up to 2 years. The other group will be actively followed up exclusively via brain MRIs for up to 2 years. |
|
|
Phase/Biobank/etc. |
|
|
Head Clinical Trial |
|
|
Study-Nurse |
|
|
Back-up |
|
|
Status |
aktive since 27.10.2022 |
|
BASEC-Nummer |
2022-00157 |
|
KOFAM |
SNCTP000004998 |
|
WHO-Register-Nummer |
NCT04790253 |
|
Insel-Nummer |
5206 |
ETOP 23-22 RAISE
|
Title in German |
Eine klinische Studie zur Untersuchung der Wirkung von Niraparib und Immuntherapie bei Patienten mit SLFN11-positivem, kleinzelligem Lungenkrebs |
|
Title in English |
A single-arm phase II trial of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer. |
|
Description |
The ETOP 23-22 RAISE clinical trial is designed for patients with a type of lung cancer called small cell lung cancer (SCLC). In addition, the lung cancer must be positive for the biomarker SLFN11. The usual therapy for patients with newly diagnosed “small cell lung cancer” is chemotherapy and immunotherapy. In order to take part in the RAISE study, you must have received standard chemotherapy and immunotherapy. In addition, continued immunotherapy treatment must be planned. In the RAISE study, we want to test whether niraparib helps prevent the regrowth of SLFN11-positive lung cancer when given in addition to immunotherapy. We also want to determine whether the side effects of this treatment are tolerable. The study will involve 44 patients at approximately 20 hospitals in 5 countries in Europe. In Switzerland it is planned that 14 patients will take part. |
|
Phase |
2 |
|
Head Clinical Trial |
|
|
Study Nurse |
|
|
Back up |
|
|
Status |
open for patient recruitment since 11.04.2024 |
|
BASEC-Nummer |
2023-01599 |
|
WHO-Register-Nummer |
|
|
Insel-Nummer |
5644 |
ETOP adopt
|
Title in German |
Eine Studie zur Beurteilung des Nutzens der Hinzufügung von Durvalumab nach Chemotherapie, Durvalumab und Operation bei Patienten mit chirurgisch behandelbarem, nicht-kleinzelligem Lungenkrebs im Frühstadium. |
|
Title in English |
An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC |
|
Description |
The ADOPT-lung study is a clinical trial for people with non-small cell lung cancer whose disease has not yet spread to other parts of the body. This disease is usually treated with surgery, which involves removing the actual tumor and surrounding lymph nodes. After surgery, patients often receive chemotherapy or immunotherapy to prevent the lung cancer from coming back. Some people also receive this treatment before surgery to shrink the tumor and make the surgery more effective. In a recent clinical trial, the immunotherapy drug durvalumab (Imfinzi®) was shown to be highly effective in preventing the lung cancer from coming back. However, it is currently unknown whether the effect of durvalumab is due to treatment before or after lung surgery, or to both treatments. In this clinical trial, we want to find out whether additional treatment with durvalumab (Imfinzi®) after surgery is necessary. The study will involve 520 patients from approximately nine countries. Seventy patients are planned to participate in Switzerland. |
|
Phase/Biobank/etc. |
3 |
|
Head Clinical Trial |
|
|
Study-Nurse |
|
|
Back-up |
|
|
Status |
open for patient recruitment |
|
BASEC-Nummer |
2024-00853 |
|
KOFAM |
SNCTP000006297 |
|
WHO-Register-Nummer |
EUCTR2023-508773-82 |
|
Insel-Nummer |
Evaluation of Fluid Output Threshold for Safe Chest Tube Removal
|
Title in German |
Überprüfung der Flüssigkeitsmenge unter der die sichere Entfernung der Thoraxdrainage erfolgen kann – Eine Möglichkeit den Spitalaufenthalt zu verkürzen und die Schmerzen zu verbessern? Ein randomisierter kontrollierter Trial. |
|
Title in English |
Evaluation of Fluid Output Threshold for Safe Chest Tube Removal - A Potential Way to Decrease Length of Stay in Hospital and to Improve Postoperative Care After Lung Surgery? |
|
Description |
After partial lung removal, chest tubes (drainage tubes) are needed to help the lungs expand and prevent fluid from accumulating around the lungs. If there is no air supply, pay attention to the amount of fluid before removing the chest tube. Fluid is physiologically produced in the space between the lungs and the chest wall (pleural space) and swallowed again, so the question remains as to what amount of fluid can be removed from the tube without leaving too much fluid behind. Depending on the amount, remaining fluid can have an impact on the breathing situation. However, the inserted chest tube is also limiting. As long as the drainage is in place, the patient is tied to hospital care and requires additional pain therapy. Our goal is to be able to remove chest tubes as quickly as possible without taking unnecessary risks. |
|
Phase/Biobank/etc. |
|
|
Head Clinical Trial |
|
|
Study-Nurse |
|
|
Back-up |
|
|
Status |
open since 07/2019 |
|
BASEC-Nummer |
2017-00527 |
|
KOFAM |
|
|
WHO-Register-Nummer |
|
|
Insel-Nummer |
3728 |
PACIFIC-8
|
Title in German |
PACIFIC-8 |
|
Title in English |
PACIFIC-8 |
|
Description |
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy (PACIFIC-8) |
|
Phase |
III |
|
Head Clincal Trial |
|
|
Study Nurse |
|
|
Back-up |
|
|
Status |
open for patient recruitment since April 2024 |
|
BASEC-Nummer |
|
|
Nummer aus Studienregister (z.B. clinicaltrials.gov) |
|
|
WHO-Register-Nummer |
|
|
Insel-Nummer |
Pfizer C5751003
|
Title in German |
|
|
Title in English |
An Open-Label, Randomized, Controlled Phase 3 Study of Sigvotatug Vedotin in Combination with Pembrolizumab Compared with Pembrolizumab Monotherapy as First-Line Treatment in Participants with PDLl High (>50% of Tumor Cells Expressing PD-LI)r Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (Be6A Lung-O2) |
|
Description |
|
|
Phase |
3 |
|
Head Clinical Trial |
|
|
Wissenschaftliche Mitarbeiterin |
|
|
Back-up |
|
|
Status |
open |
|
BASEC number |
2025-01048 |
|
Kofam number |
SNCTP000006530 |
|
WHO registry number |
HumRes67132 |
|
Insel number |
6211 |
SAKK LuCa 2
|
Title in German |
Retrospektive und prospektive Registrierung von Patienten mit metastasiertem NSCLC, die typische und atypische EGFR-Mutationen aufweisen |
|
Title in English |
Retrospective and prospective registry of patients with metastatic NSCLC harboring typical and atypical EGFR mutations |
|
Description |
|
|
Phase |
Register |
|
Head Clinical Trial |
|
|
Study Coordinator |
|
|
Status |
active since 27.06.2023 |
|
BASEC-Nummer |
2023-00398 |
|
Insel-Nummer |
5487 |